Clearstead Trust’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $147K | Sell |
2,423
-14
| -0.6% | -$816 | 0.02% | 207 |
|
|
2025
Q4 | $131K | Sell |
2,437
-276
| -10% | -$13.3K | 0.02% | 223 |
|
|
2025
Q3 | $122K | Sell |
2,713
-598
| -18% | -$27.9K | 0.02% | 222 |
|
|
2025
Q2 | $153K | Buy |
3,311
+593
| +22% | +$29.1K | 0.03% | 198 |
|
|
2025
Q1 | $166K | Sell |
2,718
-1,002
| -27% | -$58.4K | 0.04% | 171 |
|
|
2024
Q4 | $210K | Buy |
3,720
+12
| +0.3% | +$670 | 0.05% | 147 |
|
|
2024
Q3 | $192K | Buy |
3,708
+13
| +0.4% | +$610 | 0.05% | 139 |
|
|
2024
Q2 | $153K | Buy |
3,695
+14
| +0.4% | +$626 | 0.04% | 147 |
|
|
2024
Q1 | $200K | Buy |
3,681
+13
| +0.4% | +$662 | 0.05% | 133 |
|
|
2023
Q4 | $188K | Buy |
3,668
+12
| +0.3% | +$630 | 0.05% | 158 |
|
|
2023
Q3 | $212K | Buy |
3,656
+860
| +31% | +$52.7K | 0.07% | 118 |
|
|
2023
Q2 | $184K | Buy |
2,796
+9
| +0.3% | +$604 | 0.06% | 132 |
|
|
2023
Q1 | $193K | Buy |
2,787
+8
| +0.3% | +$564 | 0.06% | 134 |
|
|
2022
Q4 | $200K | Sell |
2,779
-494
| -15% | -$37.2K | 0.07% | 125 |
|
|
2022
Q3 | $232K | Buy |
3,273
+2,213
| +209% | +$161K | 0.08% | 115 |
|
|
2022
Q2 | $82K | Hold |
1,060
| – | – | 0.06% | 110 |
|
|
2022
Q1 | $77K | Hold |
1,060
| – | – | 0.05% | 114 |
|
|
2021
Q4 | $66K | Hold |
1,060
| – | – | 0.04% | 122 |
|
|
2021
Q3 | $63K | Hold |
1,060
| – | – | 0.04% | 127 |
|
|
2021
Q2 | $71K | Buy |
+1,060
| New | +$69.1K | 0.05% | 110 |
|
|
2021
Q1 | – | Sell |
-1,060
| Closed | -$66K | – | 111 |
|
|
2020
Q4 | $66K | Hold |
1,060
| – | – | 0.04% | 125 |
|
|
2020
Q3 | $64K | Hold |
1,060
| – | – | 0.05% | 114 |
|
|
2020
Q2 | $62K | Hold |
1,060
| – | – | 0.05% | 116 |
|
|
2020
Q1 | $59K | Hold |
1,060
| – | – | 0.05% | 119 |
|
|
2019
Q4 | $68K | Hold |
1,060
| – | – | 0.05% | 126 |
|
|
2019
Q3 | $54K | Hold |
1,060
| – | – | 0.04% | 129 |
|
|
2019
Q2 | $48K | Hold |
1,060
| – | – | 0.04% | 130 |
|
|
2019
Q1 | $51K | Sell |
1,060
-67
| -6% | -$3.34K | 0.04% | 130 |
|
|
2018
Q4 | $59K | Sell |
1,127
-118
| -9% | -$6.34K | 0.05% | 135 |
|
|
2018
Q3 | $77K | Sell |
1,245
-411
| -25% | -$24.4K | 0.06% | 123 |
|
|
2018
Q2 | $92K | Buy |
+1,656
| New | +$89.4K | 0.08% | 118 |
|
|
2018
Q1 | – | Sell |
-1,987
| Closed | -$122K | – | 126 |
|
|
2017
Q4 | $122K | Hold |
1,987
| – | – | 0.08% | 123 |
|
|
2017
Q3 | $127K | Hold |
1,987
| – | – | 0.09% | 130 |
|
|
2017
Q2 | $111K | Buy |
+1,987
| New | +$108K | 0.09% | 123 |
|
Other funds holding BMY
VCM
VPM
Clearstead Trust's BMY Position: Q1 2026 in Review
Clearstead Trust reduced its Bristol-Myers Squibb (BMY) stake by 0.57% in Q1 2026, selling an estimated $816 and leaving 2,423 shares worth $147K. The position accounts for 0.02% of the portfolio, ranked #207.
Clearstead Trust first reported a position in BMY in Q2 2017 and has held it in 34 quarters since. The position peaked at $232K in Q3 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Clearstead Trust held 2,423 shares of Bristol-Myers Squibb worth $147K as of Q1 2026.
- Clearstead Trust sold 14 Bristol-Myers Squibb shares in Q1 2026, an estimated $816.
- Bristol-Myers Squibb made up 0.02% of Clearstead Trust's portfolio in Q1 2026, its #207 holding.
- Clearstead Trust first reported a position in Bristol-Myers Squibb in Q2 2017 and has held it in 34 quarters since.
- Clearstead Trust's Bristol-Myers Squibb position peaked at $232K in Q3 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Clearstead Trust's 13F filing for Q1 2026, filed 6 May 2026.